Journalists Discuss New Alzheimer’s Drug, Women’s Alcohol Use, the Hip-Hop and Opioids Link

dWeb.News Article from dWeb.News Tech News

KHN chief Washington correspondent Julie Rovner discussed the FDA’s approval of a new drug for Alzheimer’s disease on WAMU’s “1A” on Wednesday.

Click here to hear Rovner on WAMU

KHN correspondent Aneri Pattani discussed the increase in alcohol use and misuse by young women on NPR’s “All Things Considered” on Wednesday.

Click here to hear Pattani on NPRRead Pattani’s “Women Now Drink as Much as Men — And Are Prone to Sickness Sooner

KHN freelancer Harris Meyer discussed the FDA’s approval of a new drug for Alzheimer’s disease on Newsy on Tuesday and WCPN’s “The Sound of Ideas” on Wednesday.

Click here to watch Meyer on NewsyClick here to hear Meyer on WCPNRead Meyer’s “FDA Weighs Approval of a Lucrative Alzheimer’s Drug, but Benefits Are Iffy

KHN social media manager Chaseedaw Giles discussed opioid use and hip-hop music on NBC Lx’s “First Look” on Tuesday.

Click here to watch Giles on NBC LxRead Giles’ “Opioids Like ‘Lean’ Permeate Hip-Hop Culture, but Dangers Are Downplayed

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

USE OUR CONTENT

This story can be republished for free (details).

KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Mental Health, Public Health, Alzheimer’s, FDA, Substance Abuse, Women’s Health
Kaiser Health News
More Health and Wellness at http://dWeb.News

The post Journalists Discuss New Alzheimer’s Drug, Women’s Alcohol Use, the Hip-Hop and Opioids Link appeared first on dWeb.News Tech News from Daniel Webster dWeb Internet Cowboy

dWeb.NewsRead More

Similar Posts

Leave a Reply